243 related articles for article (PubMed ID: 31553876)
1. Cross-Linked Polyphenol-Based Drug Nano-Self-Assemblies Engineered to Blockade Prostate Cancer Senescence.
Nagesh PKB; Chowdhury P; Hatami E; Kumari S; Kashyap VK; Tripathi MK; Wagh S; Meibohm B; Chauhan SC; Jaggi M; Yallapu MM
ACS Appl Mater Interfaces; 2019 Oct; 11(42):38537-38554. PubMed ID: 31553876
[TBL] [Abstract][Full Text] [Related]
2. Distinct phenotypes and 'bystander' effects of senescent tumour cells induced by docetaxel or immunomodulatory cytokines.
Sapega O; Mikyšková R; Bieblová J; Mrázková B; Hodný Z; Reiniš M
Int J Oncol; 2018 Nov; 53(5):1997-2009. PubMed ID: 30226595
[TBL] [Abstract][Full Text] [Related]
3. Blockade of γ-Glutamylcyclotransferase Enhances Docetaxel Growth Inhibition of Prostate Cancer Cells.
Takagi H; Ii H; Kageyama S; Hanada E; Taniguchi K; Yoshiya T; Chano T; Kawauchi A; Nakata S
Anticancer Res; 2019 Sep; 39(9):4811-4816. PubMed ID: 31519583
[TBL] [Abstract][Full Text] [Related]
4. Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel.
Shen Z; Zhou L; Zhang C; Xu J
Cancer Lett; 2020 Jan; 468():88-101. PubMed ID: 31593800
[TBL] [Abstract][Full Text] [Related]
5. Induction of Endoplasmic Reticulum Stress-Mediated Apoptosis by Aminosteroid RM-581 Efficiently Blocks the Growth of PC-3 Cancer Cells and Tumors Resistant or Not to Docetaxel.
Maltais R; Roy J; Perreault M; Sato S; Lévesque JC; Poirier D
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681843
[TBL] [Abstract][Full Text] [Related]
6. A Novel Docetaxel-Biotin Chemical Conjugate for Prostate Cancer Treatment.
Rayan M; Shadafny S; Falah A; Falah M; Abu-Lafi S; Asli S; Rayan A
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164226
[TBL] [Abstract][Full Text] [Related]
7. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy.
Sundaram S; Durairaj C; Kadam R; Kompella UB
Mol Cancer Ther; 2009 Jun; 8(6):1655-65. PubMed ID: 19509261
[TBL] [Abstract][Full Text] [Related]
8. Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis.
Guccini I; Revandkar A; D'Ambrosio M; Colucci M; Pasquini E; Mosole S; Troiani M; Brina D; Sheibani-Tezerji R; Elia AR; Rinaldi A; Pernigoni N; Rüschoff JH; Dettwiler S; De Marzo AM; Antonarakis ES; Borrelli C; Moor AE; Garcia-Escudero R; Alajati A; Attanasio G; Losa M; Moch H; Wild P; Egger G; Alimonti A
Cancer Cell; 2021 Jan; 39(1):68-82.e9. PubMed ID: 33186519
[TBL] [Abstract][Full Text] [Related]
9. 4,5-Diphenyl-2-methyl picolinate induces cellular senescence by accumulating DNA damage and activating associated signaling pathways in gastric cancer.
Zhao Z; Shang D; Qiu L; Guo C; Li Y; Liu H; Yuan G; Tu Z
Life Sci; 2019 Dec; 238():116973. PubMed ID: 31639393
[TBL] [Abstract][Full Text] [Related]
10. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
11. TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization.
Li Y; Zhang B; Xiang L; Xia S; Kucuk O; Deng X; Boise LH; Dong JT
Theranostics; 2020; 10(17):7656-7670. PubMed ID: 32685011
[TBL] [Abstract][Full Text] [Related]
12. Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin.
Zhang Y; Dong Y; Melkus MW; Yin S; Tang SN; Jiang P; Pramanik K; Wu W; Kim S; Ye M; Hu H; Lu J; Jiang C
Mol Cancer Ther; 2018 Nov; 17(11):2341-2352. PubMed ID: 30166403
[TBL] [Abstract][Full Text] [Related]
13. Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer.
Zhu C; Zhu Q; Wu Z; Yin Y; Kang D; Lu S; Liu P
J Cell Physiol; 2018 Feb; 233(2):1104-1119. PubMed ID: 28422286
[TBL] [Abstract][Full Text] [Related]
14. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells.
Schwarze SR; Fu VX; Desotelle JA; Kenowski ML; Jarrard DF
Neoplasia; 2005 Sep; 7(9):816-23. PubMed ID: 16229804
[TBL] [Abstract][Full Text] [Related]
15. BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling.
Siddique HR; Parray A; Tarapore RS; Wang L; Mukhtar H; Karnes RJ; Deng Y; Konety BR; Saleem M
PLoS One; 2013; 8(5):e60664. PubMed ID: 23671559
[TBL] [Abstract][Full Text] [Related]
16. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
[TBL] [Abstract][Full Text] [Related]
17. Reversal of docetaxel resistance in prostate cancer by Notch signaling inhibition.
Qiu S; Deng L; Bao Y; Jin K; Tu X; Li J; Liao X; Liu Z; Yang L; Wei Q
Anticancer Drugs; 2018 Oct; 29(9):871-879. PubMed ID: 29944470
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
19. microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73.
Gao Q; Zheng J
Biomed Pharmacother; 2018 Jan; 97():528-534. PubMed ID: 29091904
[TBL] [Abstract][Full Text] [Related]
20. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer.
Nagesh PKB; Johnson NR; Boya VKN; Chowdhury P; Othman SF; Khalilzad-Sharghi V; Hafeez BB; Ganju A; Khan S; Behrman SW; Zafar N; Chauhan SC; Jaggi M; Yallapu MM
Colloids Surf B Biointerfaces; 2016 Aug; 144():8-20. PubMed ID: 27058278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
